Oxford Nanopore Technologies Regulatory News (ONT)

Oxford Nanopore Technologies plc

London Calling Technology Update

Announcements highlighted breakthrough technology performance and updates to Oxford Nanopore's IVD pipeline at annual customer conference

23 May 2024

Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore" or the "Company"), the company delivering a new generation of nanopore-based molecular sensing technology, presented breakthrough performance data and new platform updates at the Company's annual London Calling customer conference, held between 21 and 24 May 2024. During the sold-out event, with more than 5,500 registered on-line and in-person participants, the Company also provided updates to its clinical product pipeline, unveiling a new roadmap for its first IVD product ahead of its first clinical and biopharma day on Friday.

Technology updates included: 

· Delivering increasingly rich, high performance multiomic data: The update focused on improved performance on accuracy, delivering complete genomes with nanopore-only Telomere-to-Telomere (T2T) sequencing, and full-length chromosomes in a single read, illustrated by successful T2T reads of four yeast chromosomes as proof of concept.

· Improving direct RNA sequencing to support breakthrough science and biopharma workflows: higher accuracy and output for direct RNA sequencing alongside the example of integrated, real-time quality control (QC) test for mRNA vaccines.

· Pipeline updates, enabling ultra-high output and accessible, distributed sequencing for anyone, anywhere: with the MinION Mk1D entering early access, continued progression with TraxION, enabling portable library prep in the field, the Voltage chip for ultra-rapid whole genome sequencing (WGS) and the new prototype of Oxford Nanopore's smallest sequencer to date - the SmidgION - which was on display at the event.

A written summary and a video replay of the technology talk can be accessed on the Oxford Nanopore website here.

This morning, the Company will present a product review including an update on progress to its regulated product pipeline. In addition to locked-down Q line devices, the GridION is expected to meet ISO 13485 standards in 2025 and the Company will seek CE-IVD certification in the EU after that. The device will be available for specified partners only. The GridION Q-Line product range is on track to launch shortly in Q3-2024, as previously announced.

Alongside the technology updates the Company will also provide more details at its first clinical and biopharma day on Friday.

[ENDS]

For further information, please contact:

Oxford Nanopore Technologies plc

Investors: ir@nanoporetech.com

Media: media@nanoporetech.com

Teneo (communications adviser to the Company)

Tom Murray, Olivia Peters

+44 (0) 20 7353 4200

OxfordNanoporeTechnologies@teneo.com

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology for real-time, high-performance, accessible and scalable analysis of DNA and RNA. The technology is used in more than 120 countries to understand the biology of humans and diseases such as cancer, plants, animals, bacteria, viruses and whole environments. Oxford Nanopore Technologies products are intended for molecular biology applications and are not intended for diagnostic purposes. www.nanoporetech.com 

Forward-looking statements

This announcement contains certain forward-looking statements. For example, statements regarding expected revenue growth and profit margins are forward-looking statements. Phrases such as "aim", "plan", "expect", "intend", "anticipate", "believe", "estimate", "target", and similar expressions of a future or forward-looking nature should also be considered forward-looking statements. Forward-looking statements address our expected future business and financial performance and financial condition, and by definition address matters that are, to different degrees, uncertain. Our results could be affected by macroeconomic conditions, the COVID-19 pandemic, delays in our receipt of components or our delivery of products to our customers, suspensions of large projects and/or acceleration of large products or accelerated adoption of pathogen surveillance. These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.